QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bombail, V. Articles by Plant, N. Search for Related Content PubMed PubMed Citation Articles by Bombail, V. Articles by Plant, N.

ROLE OF Sp1, C/EBP, HNF3, AND PXR IN THE BASAL- AND XENOBIOTIC-MEDIATED REGULATION OF THE CYP3A4 GENE

School of Biomedical and Molecular Sciences, University of Surrey, Guildford, Surrey, United Kingdom

Cytochrome P450 3A4 (CYP3A4) is the major cytochrome P450 present in adult human liver and is involved in the metabolism of over 50% of therapeutic compounds currently in use. Since expression levels of CYP3A4 are regulated by many of these compounds, this raises the potential for drug-drug interactions and subsequent altered efficacy or toxicity of the individual compounds at the dose prescribed. Hence, understanding the molecular mechanisms of CYP3A4 regulation is of key importance in predicting and understanding such interactions. To examine this we have used DNase I footprinting and bioinformatic analysis to identify putative transcription factor binding sites within the 250 base pairs of promoter proximal to the transcription start site. We identified several protected fragments within this region that corresponded to putative binding sites for Sp1, AP2, CCAAT/enhancer binding protein (C/EBP), and hepatic nuclear factor-3 (HNF3), as well as confirming previously identified C/EBP, pregnane X receptor (PXR), and HNF3 binding sites. Sequential site-directed mutagenesis of C/EBP, Sp1, HNF3, and PXR binding sites was next used to examine the role of these sites in basal CYP3A4 expression. Disruption of the C/EBP, HNF3, and PXR binding sites all affected basal expression. Finally, the role of these sites was examined in activation of CYP3A4 expression by rifampicin, metyrapone, clotrimazole, and phenobarbital. Disruption of any of these sites either led to an altered pattern of activation by the xenobiotic, as altered maximal activation, or altered the EC₅₀ value of activation. Such effects were xenobiotic-specific, with each disrupted site playing a role in the activation of some of the xenobiotics.

This article has been cited by other articles:

				J. S. Biggs, J. Wan, N. S. Cutler, J. Hakkola, P. Uusimaki, H. Raunio, and G. S. Yost Transcription Factor Binding to a Putative Double E-Box Motif Represses CYP3A4 Expression in Human Lung Cells Mol. Pharmacol., September 1, 2007; 72(3): 514 - 525. [Abstract] [Full Text] [PDF]

				W. Sadee and Z. Dai Pharmacogenetics/genomics and personalized medicine Hum. Mol. Genet., October 15, 2005; 14(suppl_2): R207 - R214. [Abstract] [Full Text] [PDF]

				T. L. Noreault, V. E. Kostrubsky, S. G. Wood, R. C. Nichols, S. C. Strom, H. W. Trask, S. A. Wrighton, R. M. Evans, J. M. Jacobs, P. R. Sinclair, et al. ARSENITE DECREASES CYP3A4 AND RXR{alpha} IN PRIMARY HUMAN HEPATOCYTES Drug Metab. Dispos., July 1, 2005; 33(7): 993 - 1003. [Abstract] [Full Text] [PDF]

				A. Phillips, S. R. Hood, G. G. Gibson, and N. J. Plant IMPACT OF TRANSCRIPTION FACTOR PROFILE AND CHROMATIN CONFORMATION ON HUMAN HEPATOCYTE CYP3A GENE EXPRESSION Drug Metab. Dispos., February 1, 2005; 33(2): 233 - 242. [Abstract] [Full Text] [PDF]